A review of contusugene ladenovec (Advexin) p53 therapy.
Explore this paper's citation graph
Summary
Contusugene ladenovec (Advexin) is a replication-impaired, non-integrating, serotype 5 adenoviral vector that carries the p53 gene under the control of the CMV promoter, providing the rationale for p53 restoration in the treatment of cancer.
- Type
- review
- Published
- 2009-02-01
- Cited by
- 47
- References
- 0
- OpenAlex
- https://openalex.org/W74998615
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:26877498
Keywords
Medicine, Cancer research, Genetic enhancement, Oncology, Hepatocellular carcinoma
References
No references recorded for this paper.
Cited by
- The Attitude of Oncology Physicians and Nurses to the Acceptance of New Drugs for Gene Therapy
- Withaferin A Targets Hsp90 in Pancreatic Cancer Cells.
- Developing an effective breast cancer vaccine.
- Targeted gene therapy for canine osteosarcoma : preliminary investigations
- New Insights into P53 Signalling and Cancer: Implications for Cancer Therapy
- The first 30 years of p53: growing ever more complex
- Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes
- Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy
- Noninvasive assessment of regulable transferred-p53 gene expression and evaluation of therapeutic response with FDG–PET in tumor model
- Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors.
- Radiation damage and radioprotectants: new concepts in the era of molecular medicine.
- Superparamagnetic iron oxide nanoparticle ‘theranostics’ for multimodality tumor imaging, gene delivery, targeted drug and prodrug delivery
- Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G0/G1 cell cycle arrest in SKBr3 breast cancer cells
- TP53 mutations in human cancers: origins, consequences, and clinical use.
- Blinded by the Light: The Growing Complexity of p53.
- A Synthetic Interaction Screen Identifies Factors Selectively Required for Proliferation and TERT Transcription in p53-Deficient Human Cancer Cells
- cAMP Signalling in Modification of DNA Damage Responses in Lymphoid Cells : Implications for Development and Treatment of BCP-ALL
- Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study.
- Genomic landscape of gastric cancer: molecular classification and potential targets
- Gene Therapy - Developments and Future Perspectives
Related papers
- Identical but different: mechanism of cancer development and response to treatment for human papillomavirus-related and non-related squamous cell cancer of the head and neck.
- Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based review
- prolonged survival with anti egfr therapy in head and neck squamous cell carcinoma a case series
- Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer.
- [Recombinant adenovirus-p53 gene therapy combined with radiotherapy for head and neck squamous-cell carcinoma].
- p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer.
- Incidence of second primary cancers after radiotherapy combined with platinum and/or cetuximab in head and neck cancer patients
- Associations of GWAS-Identified Risk Loci with Progression, Efficacy and Toxicity of Radiotherapy of Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy
- Genetically Targeted Radiotherapy of Head and Neck Squamous Cell Carcinoma
- 148 Prognostic and predictive factors in patients with advanced squamous cell head and neck cancer (HNSCC) treated with induction chemotherapy (CT) and radiotherapy (RT)